1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
CK Life Sciences International (Holdings), Inc.

CK Life Sciences International (Holdings), Inc.

0.50
HKD
-0.01
(-1.98%)
5.48BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.52
0.52
0.51
0.51
0.49
0.54
0.52
0.51
0.56
0.55
0.55
0.57
0.56
- -
Basic EPS, GAAP
0.02
0.03
0.02
0.03
0.03
0.03
0.02
0.01
0.02
0.01
- -
-0.01
-0.02
- -
Free Cash Flow per Basic Share
0.01
0.02
- -
0.02
- -
-0.01
0.02
0.02
0.02
0.02
0.02
0.02
-0.01
- -
Dividend per Share
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
Book Value per Share
0.52
0.49
0.42
0.44
0.48
0.44
0.43
0.49
0.47
0.43
0.44
0.37
0.39
0.41
Tangible Book Value per Share
0.1
0.09
0.06
0.08
0.11
0.07
0.06
0.1
0.09
0.06
0.06
0.01
0.05
0.06
Basic Weighted Avg Shares
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
Sales/Revenue/Turnover
4,971
4,954
4,919
4,869
4,693
5,233
4,967
4,943
5,402
5,276
5,323
5,523
5,410
- -
Operating Margin (%)
6.46
6.27
5.66
6.51
3.23
7.31
5.63
1.71
4.46
4.59
4.21
1.4
-2.42
- -
Depreciation Expense
136
136
155
135
145
138
204
220
247
231
234
245
245
- -
Net Income, GAAP
229
264
219
253
258
263
182
125
163
132
17
-127
-187
- -
Effective Tax Rate (%)
22.78
15.06
25.42
26.22
14.98
28.62
12.64
- -
31.66
35.59
74.85
- -
- -
- -
Profit Margin (%)
4.61
5.32
4.45
5.2
5.51
5.03
3.66
2.53
3.01
2.5
0.32
-2.29
-3.45
- -
Working Capital
671
1,858
474
-1,216
1,190
1,309
-529
2,376
1,094
-937
892
652
-461
-292
LT Debt
2,761
4,229
2,760
925
3,403
3,893
2,773
6,117
4,920
2,820
4,709
4,749
4,173
4,305
Total Equity
5,200
4,875
4,209
4,403
4,757
4,420
4,175
4,718
4,501
4,155
4,189
3,512
3,846
4,090
Return on Invested Capital (%)
2.85
2.88
2.34
2.67
1.47
2.92
2.55
- -
1.43
1.5
0.79
- -
- -
- -
Return on Capital (%)
3.53
3.81
3.74
3.68
3.56
3.42
3.28
- -
2.12
2.28
0.97
- -
- -
- -
Return on Common Equity (%)
4.39
5.47
5.02
6.08
5.82
5.92
4.31
2.81
3.53
3.05
0.41
-3.29
-5.12
- -

Capital Structure

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1,211
2,449
2,527
LT Borrowings
4,742
3,660
3,750
LT Finance Leases
544
513
555
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9,611
9,611
9,611
Market Capitalization
8,169
7,881
5,478

Working Capital

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
3,148
3,007
3,102
Cash, Cash Equivalents & STI
798
603
536
Accounts Receivable, Net
1,065
967
1,160
Inventories
1,275
1,230
1,377
Total Current Liabilities
2,119
3,468
3,394
Payables & Accruals
- -
- -
- -
ST Debt
1,211
2,449
2,527
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.51%
-3.62%
9.53%
Free Cash Flow
-45.17%
-22.22%
-139.58%
Net Income, GAAP
-90.44%
-172.38%
47.61%
Sales/Revenue/Turnover
1.09%
1.91%
-2.04%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5,523
2025
- -
- -
5,410
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ying Choi Yu
Full Time Employees
1,920
Sector
Health technology
Industry
Pharmaceuticals: other
Address
2 Dai Fu Street Hong Kong Hong Kong
IPO Date
Jul 16, 2002
Website
ck-lifesciences.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
CK Life Sciences International (Holdings) Inc. is a biotechnology company engaged in research and development, manufacturing, commercialization, marketing, and sale of products in the pharmaceuticals, nutraceuticals, and agriculture-related sectors. Its core product offerings include cancer therapeutics, health supplements, natural healthcare products, eco-fertilizers, and crop protection products. The company focuses on human health and environmental sustainability with operations spanning North America, Asia Pacific, and other regions including Australia, Canada, New Zealand, China, Hong Kong, the United States, and the Virgin Islands. It is headquartered in Hong Kong and was founded in 2001. CK Life Sciences operates through two main segments: Agriculture-Related and Health, with nutraceuticals contributing significantly to its revenue. Recent major changes include a strategic transaction completed in 2024 involving the sale of 100% membership interests in its subsidiary related to cancer treatment, valued at around US$125 million initially with potential additional milestone payments. This transaction combines its cancer therapeutic business with a Nasdaq-listed purchaser to advance the development and commercialization of seviprotimut-L, a melanoma vaccine. Additionally, CK Life Sciences executed a merger between its Canadian drug development arm WEX Pharmaceuticals and Nasdaq-listed Virios Therapeutics, valued at approximately US$100 million via stock exchange, creating a new entity named Dogwood Therapeutics. This move aims to strengthen its presence in the biotech sector and expand access to U.S. capital markets to support clinical trials and R&D, including for products targeting cancer pain and post-viral syndromes. The company has also been involved in collaborations incorporating artificial intelligence for cancer vaccine development, partnering with Shenzhen-based AI drug discovery firm Xtalpi to enhance its tumor vaccine and diagnostic platforms. CK Life Sciences is a subsidiary of CK Hutchison Holdings and is listed on the Hong Kong Stock Exchange under the ticker 0775.HK. These developments reflect CK Life Sciences' ongoing strategic focus on oncology, innovative therapeutics, agricultural sustainability products, and expansion in global markets. Its leadership under Victor Li supports its mission to improve quality of life through biotechnology innovation and sustainable agriculture solutions.